Latest news with #nutritionalSupplements
Yahoo
02-07-2025
- Business
- Yahoo
USANA Schedules Second Quarter 2025 Earnings Release and Conference Call
SALT LAKE CITY, July 02, 2025--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website ( under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at About USANA USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at USANA also holds a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at View source version on Contacts Investor contact:Andrew MasudaInvestor Relations(801) Sign in to access your portfolio
Yahoo
19-06-2025
- Business
- Yahoo
BellRing Brands (BRBR) Dips More Than Broader Market: What You Should Know
BellRing Brands (BRBR) ended the recent trading session at $60.75, demonstrating a -3.13% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, added 0.13%. Heading into today, shares of the nutritional supplements company had lost 4% over the past month, lagging the Consumer Staples sector's loss of 0.73% and the S&P 500's gain of 0.6%. Market participants will be closely following the financial results of BellRing Brands in its upcoming release. The company's earnings per share (EPS) are projected to be $0.49, reflecting a 9.26% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $531.21 million, reflecting a 3.07% rise from the equivalent quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.2 per share and a revenue of $2.3 billion, representing changes of +13.99% and +15.21%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for BellRing Brands. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.45% decrease. At present, BellRing Brands boasts a Zacks Rank of #3 (Hold). In terms of valuation, BellRing Brands is presently being traded at a Forward P/E ratio of 28.53. This signifies a premium in comparison to the average Forward P/E of 15.47 for its industry. It is also worth noting that BRBR currently has a PEG ratio of 1.98. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Food - Miscellaneous industry was having an average PEG ratio of 1.59. The Food - Miscellaneous industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 31% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BellRing Brands Inc. (BRBR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
11-06-2025
- Business
- Globe and Mail
Adia Nutrition Inc. Introduces Cherry Payment Plans at Adia Med Clinics, Enhancing Access to Innovative Therapies
Winter Park, Florida--(Newsfile Corp. - June 11, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in healthcare and nutritional supplements, is delighted to announce the introduction of Cherry Payment Plans at its Adia Med clinics, a growing clinical chain including the flagship Adia Med of Winter Park. This innovative financing option makes cutting-edge therapies more accessible by offering flexible, affordable payment solutions. To view an enhanced version of this graphic, please visit: The Cherry Payment Plans enable patients to spread treatment costs over manageable monthly installments, reducing financial barriers to accessing transformative therapies that can enhance their overall well-being. This initiative underscores Adia Nutrition's commitment to ensuring advanced treatments are within reach for those seeking to improve their personal vitality and appearance. "Launching Cherry Payment Plans is a pivotal step toward making our therapies more inclusive," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "We believe every patient deserves access to innovative care, and these flexible payment options empower more individuals to experience the potential of treatments at Adia Med." To view an enhanced version of this graphic, please visit: Adia Med of Winter Park, which opened in January 2025, is part of a rapidly expanding clinical network dedicated to personalized care. Patients can explore Cherry Payment Plans to enhance affordability. Those interested in treatment options or financing are encouraged to fill out the contact form at For questions, inquiries, or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. A quick reminder: Adia Nutrition Inc. is presenting live today, June 11th, at 2:00 PM EST at the Life Sciences Virtual Investor Forum, hosted by About ADIA Nutrition Inc.: Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
Zawya
29-05-2025
- Business
- Zawya
Egypt's HoldiPharma partners with US-based Dawah Pharma to manufacture, export to global markets
Arab Finance: The state-owned pharmaceutical firm HoldiPharma signed a partnership agreement with US-based Dawah Pharma to establish a joint venture for the manufacturing and export of pharmaceuticals and nutritional supplements to international markets, including North America and Europe, as per a statement. The agreement was signed in the presence of Prime Minister Mostafa Madbouly, who emphasized that the deal reflects international confidence in Egyptian industry and fulfills presidential directives to bolster national strategic sectors, particularly pharmaceuticals. Under the agreement, the newly formed joint venture, 60% owned by Dawah Pharma and 40% by the Egyptian side, will begin with the export of six nutritional supplement products already approved for the US market. Future plans include manufacturing and exporting a wide range of pharmaceutical products, such as ampoules, sterile injections, ophthalmic preparations, and over-the-counter medications. The venture will utilize advanced pharmaceutical manufacturing technologies, including syrups, tablets, prefilled syringes, and transdermal patches. The company will also operate under the regulatory frameworks of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), ensuring compliance and boosting the global competitiveness of Egyptian pharmaceutical products. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
